World Alzheimer's Day 2021: The Power of Knowledge

Elsevier, 14th September 2021

World Alzheimer's Day is an international campaign organised by Alzheimer's Disease International to raise awareness and highlight issues faced by people affected by dementia. It takes place every year on September 21st and is the focus of World Alzheimer's Month.

Dementia is one of the biggest challenges we face, with nearly 50 million people living with dementia worldwide. Yet 2 out of every 3 people globally believe there is little or no understanding of dementia in their countries.The impact of World Alzheimer's Month is growing, but the stigmatisation and misinformation that surrounds dementia remains a global problem. To tackle this challenge, we need to collaborate and share best practice with one another.

In support of this year’s theme – ‘Know dementia, know Alzheimer's’ - Elsevier presents a curated, open access collection of over 70 journal articles and book chapters focused on shining a light on the warning signs of dementia and the importance of a timely diagnosis.

Elsevier,

Current Opinion in Chemical Biology, Volume 65, December 2021

Intelligent data mining as a fast way to find new purposes for existing drugs.
Elsevier,

Neurobiology of Stress, Volume 8, February 2018

Stress is a critical risk factor in the development and progression of Alzheimer's disease (AD). Furthermore, added stress drives progression and can exacerbate AD symptoms.
Elsevier,

Prostaglandins and Other Lipid Mediators, Volume 156, October 2021

This review focuses on the role of 7-ketocholesterol (7KCh) mediated neurodegenerative Alzheimer’s disease with emphasis on alterations in the lipid raft microdomain. In addition, current trends in the significant therapies related to 7KCh inhibition are highlighted.
Elsevier,

Bioorganic and Medicinal Chemistry Letters, Volume 49, 1 October 2021

An evaluation of the pharmacological potency of 2 agents which may lead to the development of treatment for Alzheimer's.
Elsevier,

Current Opinion in Chemical Biology, Volume 64, October 2021

A review of potential inhibitors of amyloid protein aggregation, one of the causes of neurodegredation.
Elsevier,

Current Opinion in Chemical Biology, Volume 64, October 2021

A review of peptide model systems used to investigate and understand the structures, biological properties, and biophysical properties of amyloid oligomers linked to diseases such as Alzheimers.
Elsevier,

Current Opinion in Chemical Biology, Volume 64, October 2021

A review of recent advances in protein chemistry, biophysics, advanced imaging, and proteomics and the way they could be applied to decipher and embrace the complexity of protein aggregation and pathology formation. This may advance translational research and drug discovery in neurodegenerative diseases.
Elsevier,

Behavioural Brain Research, Volume 414, 24 September 2021

Studies have shown that the RhoA/ROCK signaling pathway can promote Alzheimer's disease and therefore, ROCK is a promising drug target in AD.
Elsevier,

Ageing Research Reviews, Volume 70, September 2021

Multiple factors such genetics, metabolism, and lifestyle factors are involved in both COVID-19 and Alzheimer’s disease.
Elsevier,

Neurobiology of Disease, Volume 156, August 2021

This area of research represents a new therapeutic paradigm that could add functional years of life to individuals who would otherwise develop dementia.